董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Paris Panayiotopoulos | 男 | Director | 44 | 64.10万美元 | 未持股 | 2018-04-01 |
| Alexander J. Denner | 男 | Director | 48 | 36.70万美元 | 未持股 | 2018-04-01 |
| Clive A. Meanwell | 男 | Director and Chief Executive Officer | 60 | 760.79万美元 | 未持股 | 2018-04-01 |
| Fredric N. Eshelman | 男 | Director and Executive Chairman | 69 | 未披露 | 未持股 | 2018-04-01 |
| John C. Kelly | 男 | Director | 75 | 36.80万美元 | 未持股 | 2018-04-01 |
| Fredric N. Eshelman | 男 | Director and Executive Chairman | 69 | 41.82万美元 | 未持股 | 2018-04-01 |
| Geno J. Germano | 男 | Director | 57 | 32.80万美元 | 未持股 | 2018-04-01 |
| Sarah J. Schlesinger | 女 | Director | 58 | 未披露 | 未持股 | 2018-04-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Stephen M. Rodin | 男 | General Counsel and Secretary | 42 | 192.18万美元 | 未持股 | 2018-04-01 |
| Chris Cox | 男 | Executive Vice President and Chief Corporate Development Officer | 53 | 276.42万美元 | 未持股 | 2018-04-01 |
| Christopher J. Visioli | 男 | Chief Financial Officer and Treasurer | 42 | 未披露 | 未持股 | 2018-04-01 |
| Clive A. Meanwell | 男 | Director and Chief Executive Officer | 60 | 760.79万美元 | 未持股 | 2018-04-01 |
| Fredric N. Eshelman | 男 | Director and Executive Chairman | 69 | 未披露 | 未持股 | 2018-04-01 |
| Fredric N. Eshelman | 男 | Director and Executive Chairman | 69 | 41.82万美元 | 未持股 | 2018-04-01 |
董事简历
中英对照 | 中文 | 英文- Paris Panayiotopoulos
-
Paris Panayiotopoulos 自2016年1月起担任公司总裁兼首席执行官。Panayiotopoulos先生从EMD Serono, Inc. （一家位于德国达姆施塔特Merck KGaA的一家制药公司子公司）加入ARIAD，在那里2013年至2015年他担任总裁。在被任命为EMD Serono的总裁之前，2012年至2013年Panayiotopoulos先生在Merck KGaA担任越来越重要的职务，担任日本东京Merck Serono的总裁；2011年至2012年，担任瑞士日内瓦首席执行官的全球首席工作人员；2011年，担任西欧的负责人，负责生育能力和内分泌专营权；2007年至2011年，担任神经内科专营的全球总监；2004年至2007年，担任全球战略和商业智能总监。加入Merck KGaA之前，1999年至2004年Panayiotopoulos先生曾在Eli Lilly & Co。就职。
Paris Panayiotopoulos has been a director since March 2017. Mr. Panayiotopoulos is an operating partner and member of the investment team at Clarus and serves as the executive chairman of Genevant Sciences. From 2016 to 2017 Mr. Panayiotopoulos was President and Chief Executive Officer and a member of the Board of Directors of Ariad Pharmaceuticals Inc. From 2013 through 2015 Mr. Panayiotopoulos served as President of EMD Serono, Inc., a subsidiary of pharmaceutical company Merck KGaA, Darmstadt, Germany. Prior to being appointed President of EMD Serono, Mr. Panayiotopoulos held positions of increasing responsibility within Merck KGaA, serving as President of Merck Serono, Tokyo, Japan, from 2012 through 2013; Global Chief of Staff for the CEO in Geneva, Switzerland, from 2011 through 2012; Head of Western Europe for the fertility and endocrinology franchises, in 2011; Global Director of the neurology franchise, from 2007 through 2011; and Global Strategy and Business Intelligence Director from 2004 through 2007. Prior to joining Merck KGaA, Mr. Panayiotopoulos was at Eli Lilly & Co. from 1999 to 2004. While at Merck KGaA, Mr. Panayiotopoulos led multiple partnerships, including those with Pfizer Inc., Bristol Myers Squibb, Eli Lilly & Co., Dainippon Sumitomo Pharma, Mitsubishi Tanabe Pharma, Otsuka Pharmaceutical Co. Ltd. and Incyte Corporation and served on the board of directors of BIO. Mr. Panayiotopoulos holds a combined B.Sc. in Chemistry and Management Studies from University College London and a M.Sc. in Marketing and Product Management from Cranfield Business School in the United Kingdom. - Paris Panayiotopoulos 自2016年1月起担任公司总裁兼首席执行官。Panayiotopoulos先生从EMD Serono, Inc. （一家位于德国达姆施塔特Merck KGaA的一家制药公司子公司）加入ARIAD，在那里2013年至2015年他担任总裁。在被任命为EMD Serono的总裁之前，2012年至2013年Panayiotopoulos先生在Merck KGaA担任越来越重要的职务，担任日本东京Merck Serono的总裁；2011年至2012年，担任瑞士日内瓦首席执行官的全球首席工作人员；2011年，担任西欧的负责人，负责生育能力和内分泌专营权；2007年至2011年，担任神经内科专营的全球总监；2004年至2007年，担任全球战略和商业智能总监。加入Merck KGaA之前，1999年至2004年Panayiotopoulos先生曾在Eli Lilly & Co。就职。
- Paris Panayiotopoulos has been a director since March 2017. Mr. Panayiotopoulos is an operating partner and member of the investment team at Clarus and serves as the executive chairman of Genevant Sciences. From 2016 to 2017 Mr. Panayiotopoulos was President and Chief Executive Officer and a member of the Board of Directors of Ariad Pharmaceuticals Inc. From 2013 through 2015 Mr. Panayiotopoulos served as President of EMD Serono, Inc., a subsidiary of pharmaceutical company Merck KGaA, Darmstadt, Germany. Prior to being appointed President of EMD Serono, Mr. Panayiotopoulos held positions of increasing responsibility within Merck KGaA, serving as President of Merck Serono, Tokyo, Japan, from 2012 through 2013; Global Chief of Staff for the CEO in Geneva, Switzerland, from 2011 through 2012; Head of Western Europe for the fertility and endocrinology franchises, in 2011; Global Director of the neurology franchise, from 2007 through 2011; and Global Strategy and Business Intelligence Director from 2004 through 2007. Prior to joining Merck KGaA, Mr. Panayiotopoulos was at Eli Lilly & Co. from 1999 to 2004. While at Merck KGaA, Mr. Panayiotopoulos led multiple partnerships, including those with Pfizer Inc., Bristol Myers Squibb, Eli Lilly & Co., Dainippon Sumitomo Pharma, Mitsubishi Tanabe Pharma, Otsuka Pharmaceutical Co. Ltd. and Incyte Corporation and served on the board of directors of BIO. Mr. Panayiotopoulos holds a combined B.Sc. in Chemistry and Management Studies from University College London and a M.Sc. in Marketing and Product Management from Cranfield Business School in the United Kingdom.
- Alexander J. Denner
-
Alexander J. Denner， 哲学博士。2013年7月19日起，他担任公司董事。他是Sarissa Capital Management LP的创始合伙人和首席投资官， 该公司是成立于2012年的注册投资顾问公司。Sarissa Capital注重于提高公司战略，为股东提供更佳的价值。2006至2011年11月，他担任Icahn Capital的高级管理董事，该公司是Carl C. Icahn进行投资活动的实体。在此之前，他曾担任私人投资基金Viking Global Investors和全球资产管理公司摩根斯坦利投资管理（Morgan Stanley Investment Management）的投资组合经理。2009年起，他担任上市生物制药公司Biogen Idec Inc.的董事；2014年起担任上市制药公司ARIAD Pharmaceuticals, Inc.的董事。过去5年内，他曾担任以下上市公司的董事：2009至2012年，上市生物制药公司Amylin Pharmaceuticals, Inc.的董事；2009至2013年，上市生物制药公司Enzon Pharmaceuticals, Inc.的董事；2006至2008年被收购，上市生物制药公司ImClone Systems Incorporated的董事和执行委员会主席；2006至2009年，担任上市生物制药公司Mast Therapeutics, Inc.的董事，前身为Adventrx Pharmaceuticals, Inc.他在麻省理工学院（Massachusetts Institute of Technology）获得理学学士学位，在耶鲁大学（Yale University）获得理学硕士学位、哲学硕士学位和哲学博士学位。
Alexander J. Denner,is a founding partner and Chief Investment Officer of Sarissa Capital Management LP, a registered investment advisor, which he founded in 2012. Sarissa Capital focuses on improving the strategies of companies to enhance stockholder value. From 2006 to 2011, Dr. Denner served as a Senior Managing Director at Icahn Capital L.P. Prior to that, he served as a portfolio manager at Viking Global Investors, a private investment fund, and Morgan Stanley Investment Management, a global asset management firm. - Alexander J. Denner， 哲学博士。2013年7月19日起，他担任公司董事。他是Sarissa Capital Management LP的创始合伙人和首席投资官， 该公司是成立于2012年的注册投资顾问公司。Sarissa Capital注重于提高公司战略，为股东提供更佳的价值。2006至2011年11月，他担任Icahn Capital的高级管理董事，该公司是Carl C. Icahn进行投资活动的实体。在此之前，他曾担任私人投资基金Viking Global Investors和全球资产管理公司摩根斯坦利投资管理（Morgan Stanley Investment Management）的投资组合经理。2009年起，他担任上市生物制药公司Biogen Idec Inc.的董事；2014年起担任上市制药公司ARIAD Pharmaceuticals, Inc.的董事。过去5年内，他曾担任以下上市公司的董事：2009至2012年，上市生物制药公司Amylin Pharmaceuticals, Inc.的董事；2009至2013年，上市生物制药公司Enzon Pharmaceuticals, Inc.的董事；2006至2008年被收购，上市生物制药公司ImClone Systems Incorporated的董事和执行委员会主席；2006至2009年，担任上市生物制药公司Mast Therapeutics, Inc.的董事，前身为Adventrx Pharmaceuticals, Inc.他在麻省理工学院（Massachusetts Institute of Technology）获得理学学士学位，在耶鲁大学（Yale University）获得理学硕士学位、哲学硕士学位和哲学博士学位。
- Alexander J. Denner,is a founding partner and Chief Investment Officer of Sarissa Capital Management LP, a registered investment advisor, which he founded in 2012. Sarissa Capital focuses on improving the strategies of companies to enhance stockholder value. From 2006 to 2011, Dr. Denner served as a Senior Managing Director at Icahn Capital L.P. Prior to that, he served as a portfolio manager at Viking Global Investors, a private investment fund, and Morgan Stanley Investment Management, a global asset management firm.
- Clive A. Meanwell
-
Clive A. Meanwell是一位创始人，自1996年以来一直担任董事。他自2012年2月起担任Metsera，Inc.首席执行官，2009年10月至2012年2月担任Metsera，Inc.首席执行官兼总裁，2004年8月至2009年10月担任Metsera，Inc.总裁，2004年8月至2004年12月担任Metsera，Inc.执行董事长，2001年9月至2004年8月担任Metsera，Inc.执行董事长，1996年至2001年9月担任Metsera，Inc.首席执行官兼总裁。Meanwell博士还曾于2001年9月至2015年8月担任Metsera，Inc.董事会主席。Meanwell博士是瑞士投资公司BB Biotech的副董事长。从1995年到1996年，Meanwell博士是风险投资公司MPM Capital，L.P.的合伙人兼董事总经理。1986-1995年，Meanwell博士在制药公司Hoffmann-La Roche，Inc.担任过多个职位，包括1992-1995年的高级副总裁、1991-1992年的副总裁和1986-1991年的产品开发总监。Meanwell博士在英国伯明翰大学获得医学博士、工商管理硕士和博士学位（M.D。）。
Clive A. Meanwell,has served as Metsera, Inc. Executive Chairman of the Board of Directors since September 2024 and as Metsera, Inc. Founder and a member of Metsera, Inc. board of directors since Metsera, Inc. inception in June 2022. Dr. Meanwell previously served as Metsera, Inc. Chief Executive Officer from March 2023 to September 2024. Dr. Meanwell has served as a director of Fractyl Health, Inc., a publicly-held metabolic therapeutics company since June 2021. Dr. Meanwell is a Co-Founder of Population Health Partners, L.P., a life sciences investment firm, and, since May 2020 has served as its Chairman and Managing Partner, as well as a managing member of Population Health Partners GP, LLC, its General Partner. Since January 2003, Dr. Meanwell has served as Vice Chairman of BB Biotech AG, a publicly-held Swiss biotechnology investment company, where he has also served as a director since 2004. Dr. Meanwell founded and served as Executive Chairman, Chief Executive Officer, and Director of The Medicines Company, a biopharmaceutical company focused on cardiovascular and infectious diseases and surgery, from 1997 to December 2018, and as a Director and Chief Innovation Officer from December 2018 to January 2020, prior to its sale to Novartis in January 2020. Prior to his founding of The Medicines Company, Dr. Meanwell was a Partner at MPM Capital, a venture capital firm. Before then, he held leadership roles of increasing scope at Roche worldwide, culminating as Senior Vice President and Director in the pharmaceutical division. Dr. Meanwell began his career in cancer treatment and research. He holds an M.B., Ch.B. and M.D. magna cum laude from the University of Birmingham, United Kingdom. - Clive A. Meanwell是一位创始人，自1996年以来一直担任董事。他自2012年2月起担任Metsera，Inc.首席执行官，2009年10月至2012年2月担任Metsera，Inc.首席执行官兼总裁，2004年8月至2009年10月担任Metsera，Inc.总裁，2004年8月至2004年12月担任Metsera，Inc.执行董事长，2001年9月至2004年8月担任Metsera，Inc.执行董事长，1996年至2001年9月担任Metsera，Inc.首席执行官兼总裁。Meanwell博士还曾于2001年9月至2015年8月担任Metsera，Inc.董事会主席。Meanwell博士是瑞士投资公司BB Biotech的副董事长。从1995年到1996年，Meanwell博士是风险投资公司MPM Capital，L.P.的合伙人兼董事总经理。1986-1995年，Meanwell博士在制药公司Hoffmann-La Roche，Inc.担任过多个职位，包括1992-1995年的高级副总裁、1991-1992年的副总裁和1986-1991年的产品开发总监。Meanwell博士在英国伯明翰大学获得医学博士、工商管理硕士和博士学位（M.D。）。
- Clive A. Meanwell,has served as Metsera, Inc. Executive Chairman of the Board of Directors since September 2024 and as Metsera, Inc. Founder and a member of Metsera, Inc. board of directors since Metsera, Inc. inception in June 2022. Dr. Meanwell previously served as Metsera, Inc. Chief Executive Officer from March 2023 to September 2024. Dr. Meanwell has served as a director of Fractyl Health, Inc., a publicly-held metabolic therapeutics company since June 2021. Dr. Meanwell is a Co-Founder of Population Health Partners, L.P., a life sciences investment firm, and, since May 2020 has served as its Chairman and Managing Partner, as well as a managing member of Population Health Partners GP, LLC, its General Partner. Since January 2003, Dr. Meanwell has served as Vice Chairman of BB Biotech AG, a publicly-held Swiss biotechnology investment company, where he has also served as a director since 2004. Dr. Meanwell founded and served as Executive Chairman, Chief Executive Officer, and Director of The Medicines Company, a biopharmaceutical company focused on cardiovascular and infectious diseases and surgery, from 1997 to December 2018, and as a Director and Chief Innovation Officer from December 2018 to January 2020, prior to its sale to Novartis in January 2020. Prior to his founding of The Medicines Company, Dr. Meanwell was a Partner at MPM Capital, a venture capital firm. Before then, he held leadership roles of increasing scope at Roche worldwide, culminating as Senior Vice President and Director in the pharmaceutical division. Dr. Meanwell began his career in cancer treatment and research. He holds an M.B., Ch.B. and M.D. magna cum laude from the University of Birmingham, United Kingdom.
- Fredric N. Eshelman
-
Fredric N. Eshelman，2009年7月起，担任本公司的执行董事长。1990年7月至2009年7月，他担任本公司的首席执行官；1993年7月至2009年7月，担任副董事长。他是本公司前身的创始人，并担任首席执行官，直到1989年将其出售给本公司。回到本公司之前，1989-1990，他是Glaxo Holdings plc子公司Glaxo Inc.的开发高级副总裁、董事。他现为Furiex Pharmaceuticals, Inc.的董事长、顾问。
Fredric N. Eshelman,Dr. Eshelman was the founder of Pharmaceutical Product Development, Inc. PPD and founding chairman of Furiex Pharmaceuticals, Inc. In 2014 Dr. Eshelman founded Eshelman Ventures, LLC, an investment company focused on healthcare companies. From 2009 to 2014 Dr. Eshelman served as chairman of the Board of Furiex. From 2009 to 2011 he served as executive chairman of PPD. He also served as chief executive officer of PPD from 1990 to 2009 and as vice chairman of its Board of Directors from 1993 to 2009. Dr. Eshelman currently serves on the board of directors of Valeant Pharmaceuticals International, Inc. and G1 Therapeutics, Inc. Dr. Eshelman received a bachelor’s degree in pharmacy from UNC Chapel Hill and a doctorate in pharmacy from the University of Cincinnati, and he completed an OPM program at Harvard University. - Fredric N. Eshelman，2009年7月起，担任本公司的执行董事长。1990年7月至2009年7月，他担任本公司的首席执行官；1993年7月至2009年7月，担任副董事长。他是本公司前身的创始人，并担任首席执行官，直到1989年将其出售给本公司。回到本公司之前，1989-1990，他是Glaxo Holdings plc子公司Glaxo Inc.的开发高级副总裁、董事。他现为Furiex Pharmaceuticals, Inc.的董事长、顾问。
- Fredric N. Eshelman,Dr. Eshelman was the founder of Pharmaceutical Product Development, Inc. PPD and founding chairman of Furiex Pharmaceuticals, Inc. In 2014 Dr. Eshelman founded Eshelman Ventures, LLC, an investment company focused on healthcare companies. From 2009 to 2014 Dr. Eshelman served as chairman of the Board of Furiex. From 2009 to 2011 he served as executive chairman of PPD. He also served as chief executive officer of PPD from 1990 to 2009 and as vice chairman of its Board of Directors from 1993 to 2009. Dr. Eshelman currently serves on the board of directors of Valeant Pharmaceuticals International, Inc. and G1 Therapeutics, Inc. Dr. Eshelman received a bachelor’s degree in pharmacy from UNC Chapel Hill and a doctorate in pharmacy from the University of Cincinnati, and he completed an OPM program at Harvard University.
- John C. Kelly
-
John C. Kelly担任Pfizer 制药产品有限公司的前高级副总裁和金融官。 Mr. Kelly从2009年10月至2010年2月担任Pfizer 有限公司的高级副总裁和金融，自2008年3月担任Wyeth公司（制药和健康保健产品）公司副总裁和监管员。Mr. Kelly自2002年加入Wyeth担任多种职务，包括副总裁、金融运营官。他还担任The Medicines Company的董事。Mr. Kelly担任审计委员会和金融委员会的成员。Mr. Kelly因其40年金融审计经验和其卫生保健的背景，被提名担任特别小组的成员 。在加入 Wyeth （而后加入 Pfizer）之前，他处理广泛的金融合同，在Arthur Andersen公共审计超过35年，担任多个领导职务，包括在纽约城市区域担任管理审计合作伙伴和商业顾问。他是有资格公共会计员和美国公共会计师认证监管委员会被选举的成员 。他在 Seton Hall大学获得经济管理的理学学士学位。
John C. Kelly has been a director since April 2011 and served as our lead director from May 2015 to August 2015. From October 2009 to February 2010 Mr. Kelly served as senior vice president, finance of Pfizer Inc., or Pfizer. From March 2008 to October 2009 Mr. Kelly served as vice president and controller at Wyeth and from June 2002 to March 2008 he served as vice president, financial operations of Wyeth. Prior to joining Wyeth in 2002 he spent more than 35 years in public accounting at Arthur Andersen in various leadership capacities, including as the partner in charge of audit and business consulting practices in the New York metropolitan area. Mr. Kelly previously served as a director of C.R. Bard, Inc., a medical device company, and a subsidiary of Horizon Blue Cross Blue Shield of New Jersey. He is a certified public accountant and was an elected member of the Council of the American Institute of Certified Public Accountants. Mr. Kelly received a B.S. in business administration and an M.B.A. in international finance from Seton Hall University. - John C. Kelly担任Pfizer 制药产品有限公司的前高级副总裁和金融官。 Mr. Kelly从2009年10月至2010年2月担任Pfizer 有限公司的高级副总裁和金融，自2008年3月担任Wyeth公司（制药和健康保健产品）公司副总裁和监管员。Mr. Kelly自2002年加入Wyeth担任多种职务，包括副总裁、金融运营官。他还担任The Medicines Company的董事。Mr. Kelly担任审计委员会和金融委员会的成员。Mr. Kelly因其40年金融审计经验和其卫生保健的背景，被提名担任特别小组的成员 。在加入 Wyeth （而后加入 Pfizer）之前，他处理广泛的金融合同，在Arthur Andersen公共审计超过35年，担任多个领导职务，包括在纽约城市区域担任管理审计合作伙伴和商业顾问。他是有资格公共会计员和美国公共会计师认证监管委员会被选举的成员 。他在 Seton Hall大学获得经济管理的理学学士学位。
- John C. Kelly has been a director since April 2011 and served as our lead director from May 2015 to August 2015. From October 2009 to February 2010 Mr. Kelly served as senior vice president, finance of Pfizer Inc., or Pfizer. From March 2008 to October 2009 Mr. Kelly served as vice president and controller at Wyeth and from June 2002 to March 2008 he served as vice president, financial operations of Wyeth. Prior to joining Wyeth in 2002 he spent more than 35 years in public accounting at Arthur Andersen in various leadership capacities, including as the partner in charge of audit and business consulting practices in the New York metropolitan area. Mr. Kelly previously served as a director of C.R. Bard, Inc., a medical device company, and a subsidiary of Horizon Blue Cross Blue Shield of New Jersey. He is a certified public accountant and was an elected member of the Council of the American Institute of Certified Public Accountants. Mr. Kelly received a B.S. in business administration and an M.B.A. in international finance from Seton Hall University.
- Fredric N. Eshelman
-
Fredric N. Eshelman，他是一名药学博士。自本公司于2009年成立以来，他在本公司担任董事会主席。自2009年7月至2011年12月，他在Pharmaceutical Product Development公司 （"PPD"）担任董事会执行主席。该公司于2011年12月进行资本清算。自1990年7月至2009年7月，他在PPD公司担任首席执行官。自1993年7月至2009年7月，他担任董事会副总裁。他建立了PPD公司的前身公司并担任了首席执行官，直至1989年该公司被PPD公司收购。自1989年至1990年，他在Glaxo公司担任开发方面的高级副总裁以及董事。Glaxo公司是Glaxo Holdings plc公司的子公司。他在美国北卡罗来纳州生物技术中心担任董事。
Fredric N. Eshelman,was appointed the Executive Chairman of Aravive, Inc. on January 3, 2022 and has served as the non-executive Chairman of the Board of Directors from April 8, 2020 until his appointment as Executive Chairman of Aravive, Inc. Dr. Eshelman is the Founder of Eshelman Ventures, LLC, an investment company primarily interested in healthcare companies. Previously, he founded and served as Chairman and Chief Executive Officer of Pharmaceutical Product Development, Inc. (PPDI) prior to the sale of the company to private equity interests. After PPD, he served as founding chairman and was the largest shareholder of Furiex Pharmaceuticals, Inc. (FURX), a company which in-licensed and rapidly developed new medicines. Furiex was sold to Forest Laboratories Inc. (which was later acquired by Actavis) in 2014. His career has also included positions as SVP development and board member of the former Glaxo, Inc., as well as management positions with Beecham Laboratories and Boehringer Mannheim Pharmaceuticals. Dr. Eshelman is also a member of the Board of Directors of, Amplitude Healthcare Acquisition Corp. and Eyenovia Inc. He is currently chairman of several biotech companies and previously was chairman of The Medicines Company (MDCO) and was on the board of Bausch Health (BHC) G1 Therapeutics, Inc. Dr. Eshelman has served on the executive committee of the Medical Foundation of North Carolina and was appointed by the North Carolina General Assembly to serve on the Board of Governors for the state's multi-campus university system (chair of audit committee), as well as the North Carolina Biotechnology Center. In addition, he chairs the board of visitors for the School of Pharmacy at University of North Carolina at Charlotte (UNC-CH). The school was named the UNC Eshelman School of Pharmacy in recognition of his many contributions to the school and the profession.He has received many awards including the Davie and Distinguished Service Awards from UNC, outstanding alumnus from both the UNC and University of Cincinnati schools of pharmacy, Life Science Leadership Award (CED) and the North Carolina Biotech Hall of Fame. Dr. Eshelman received the doctor of pharmacy from the University of Cincinnati, completed a residency at Cincinnati General Hospital, and received a BS Pharm from UNC-CH. He completed the OPM program at Harvard Business School. Dr. Eshelman also received an honorary doctor of science from UNC-CH. - Fredric N. Eshelman，他是一名药学博士。自本公司于2009年成立以来，他在本公司担任董事会主席。自2009年7月至2011年12月，他在Pharmaceutical Product Development公司 （"PPD"）担任董事会执行主席。该公司于2011年12月进行资本清算。自1990年7月至2009年7月，他在PPD公司担任首席执行官。自1993年7月至2009年7月，他担任董事会副总裁。他建立了PPD公司的前身公司并担任了首席执行官，直至1989年该公司被PPD公司收购。自1989年至1990年，他在Glaxo公司担任开发方面的高级副总裁以及董事。Glaxo公司是Glaxo Holdings plc公司的子公司。他在美国北卡罗来纳州生物技术中心担任董事。
- Fredric N. Eshelman,was appointed the Executive Chairman of Aravive, Inc. on January 3, 2022 and has served as the non-executive Chairman of the Board of Directors from April 8, 2020 until his appointment as Executive Chairman of Aravive, Inc. Dr. Eshelman is the Founder of Eshelman Ventures, LLC, an investment company primarily interested in healthcare companies. Previously, he founded and served as Chairman and Chief Executive Officer of Pharmaceutical Product Development, Inc. (PPDI) prior to the sale of the company to private equity interests. After PPD, he served as founding chairman and was the largest shareholder of Furiex Pharmaceuticals, Inc. (FURX), a company which in-licensed and rapidly developed new medicines. Furiex was sold to Forest Laboratories Inc. (which was later acquired by Actavis) in 2014. His career has also included positions as SVP development and board member of the former Glaxo, Inc., as well as management positions with Beecham Laboratories and Boehringer Mannheim Pharmaceuticals. Dr. Eshelman is also a member of the Board of Directors of, Amplitude Healthcare Acquisition Corp. and Eyenovia Inc. He is currently chairman of several biotech companies and previously was chairman of The Medicines Company (MDCO) and was on the board of Bausch Health (BHC) G1 Therapeutics, Inc. Dr. Eshelman has served on the executive committee of the Medical Foundation of North Carolina and was appointed by the North Carolina General Assembly to serve on the Board of Governors for the state's multi-campus university system (chair of audit committee), as well as the North Carolina Biotechnology Center. In addition, he chairs the board of visitors for the School of Pharmacy at University of North Carolina at Charlotte (UNC-CH). The school was named the UNC Eshelman School of Pharmacy in recognition of his many contributions to the school and the profession.He has received many awards including the Davie and Distinguished Service Awards from UNC, outstanding alumnus from both the UNC and University of Cincinnati schools of pharmacy, Life Science Leadership Award (CED) and the North Carolina Biotech Hall of Fame. Dr. Eshelman received the doctor of pharmacy from the University of Cincinnati, completed a residency at Cincinnati General Hospital, and received a BS Pharm from UNC-CH. He completed the OPM program at Harvard Business School. Dr. Eshelman also received an honorary doctor of science from UNC-CH.
- Geno J. Germano
-
GenoJ.Germano自2017年11月起担任董事。Germano先生最近于2016年6月1日至2017年3月担任合成生物学领导者Intrexon Corporation的总裁。他此前曾担任Pfizer，Inc.的全球创新制药业务集团总裁，在那里他曾领导一个不断增长的全球140亿美元的业务，涉及市场领先的药物，以及多个治疗领域的广泛的后期开发候选产品组合，包括心血管、代谢疾病、神经科学、炎症、免疫学、以及罕见的疾病。Germano先生也是辉瑞公司（Pfizer&8217；）的投资组合战略和投资委员会的联合主席，在此之前，是辉瑞公司（Pfizer&8217；）的专业护理和肿瘤业务部门的总裁兼总经理。在加入辉瑞公司之前，Germano先生在惠氏制药公司担任过许多行政和领导职务，包括惠氏美国公司的总裁，他在该公司负责四个业务部门的运营成果的交付，以及该公司全球制药和妇女梦百合业务的总裁。Germano先生一直是五十国集团（Group of Fifty G50）的成员，并在生物技术创新组织（Biotechnology Innovation Organization）的董事会任职，在那里他是执行委员会的成员并主持国际委员会。他是梦百合女商人协会的顾问委员会成员，并于2008年10月至2017年10月担任奥尔巴尼药学院的受托人，在那里获得药学理学学士学位。Germano先生以前是硕腾公司的董事，目前是BioverativInc.和Sage Therapeutics的董事。
Geno J. Germano has been a director since November 2017. Mr. Germano was, most recently, President of Intrexon Corporation, a leader in synthetic biology, from June 1 2016 to March 2017. He previously held the position of Group President of the Global Innovative Pharma Business of Pfizer, Inc., where he led a growing global $14 billion business with market-leading medicines and an extensive portfolio of late-stage development candidates in several therapeutic areas, including cardiovascular, metabolic disease, neuroscience, inflammation, immunology, and rare diseases. Mr. Germano was also Co-Chair of Pfizer’s Portfolio Strategy and Investment Committee and, prior to that, President and General Manager of Pfizer’s Specialty Care and Oncology business units. Prior to joining Pfizer, Mr. Germano held numerous executive and leadership roles at Wyeth Pharmaceuticals, including President of Wyeth U.S., where he was responsible for the delivery of operational results across four business units, as well as President of its Global Pharmaceutical and Women’s Healthcare Business. Mr. Germano has been a member of the Group of Fifty G50 and served on the Board of the Biotechnology Innovation Organization, where he was a member of the Executive Committee and Chaired the International Committee. He serves on the Advisory Board of the Healthcare Businesswomen’s Association and was a Trustee of the Albany College of Pharmacy from October 2008 to October 2017 where he received his Bachelor of Science degree in Pharmacy. Mr. Germano was formerly a director of Zoetis Inc. and is currently a director of Bioverativ Inc. and Sage Therapeutics. - GenoJ.Germano自2017年11月起担任董事。Germano先生最近于2016年6月1日至2017年3月担任合成生物学领导者Intrexon Corporation的总裁。他此前曾担任Pfizer，Inc.的全球创新制药业务集团总裁，在那里他曾领导一个不断增长的全球140亿美元的业务，涉及市场领先的药物，以及多个治疗领域的广泛的后期开发候选产品组合，包括心血管、代谢疾病、神经科学、炎症、免疫学、以及罕见的疾病。Germano先生也是辉瑞公司（Pfizer&8217；）的投资组合战略和投资委员会的联合主席，在此之前，是辉瑞公司（Pfizer&8217；）的专业护理和肿瘤业务部门的总裁兼总经理。在加入辉瑞公司之前，Germano先生在惠氏制药公司担任过许多行政和领导职务，包括惠氏美国公司的总裁，他在该公司负责四个业务部门的运营成果的交付，以及该公司全球制药和妇女梦百合业务的总裁。Germano先生一直是五十国集团（Group of Fifty G50）的成员，并在生物技术创新组织（Biotechnology Innovation Organization）的董事会任职，在那里他是执行委员会的成员并主持国际委员会。他是梦百合女商人协会的顾问委员会成员，并于2008年10月至2017年10月担任奥尔巴尼药学院的受托人，在那里获得药学理学学士学位。Germano先生以前是硕腾公司的董事，目前是BioverativInc.和Sage Therapeutics的董事。
- Geno J. Germano has been a director since November 2017. Mr. Germano was, most recently, President of Intrexon Corporation, a leader in synthetic biology, from June 1 2016 to March 2017. He previously held the position of Group President of the Global Innovative Pharma Business of Pfizer, Inc., where he led a growing global $14 billion business with market-leading medicines and an extensive portfolio of late-stage development candidates in several therapeutic areas, including cardiovascular, metabolic disease, neuroscience, inflammation, immunology, and rare diseases. Mr. Germano was also Co-Chair of Pfizer’s Portfolio Strategy and Investment Committee and, prior to that, President and General Manager of Pfizer’s Specialty Care and Oncology business units. Prior to joining Pfizer, Mr. Germano held numerous executive and leadership roles at Wyeth Pharmaceuticals, including President of Wyeth U.S., where he was responsible for the delivery of operational results across four business units, as well as President of its Global Pharmaceutical and Women’s Healthcare Business. Mr. Germano has been a member of the Group of Fifty G50 and served on the Board of the Biotechnology Innovation Organization, where he was a member of the Executive Committee and Chaired the International Committee. He serves on the Advisory Board of the Healthcare Businesswomen’s Association and was a Trustee of the Albany College of Pharmacy from October 2008 to October 2017 where he received his Bachelor of Science degree in Pharmacy. Mr. Germano was formerly a director of Zoetis Inc. and is currently a director of Bioverativ Inc. and Sage Therapeutics.
- Sarah J. Schlesinger
-
Sarah J. Schlesinger医学博士在细胞免疫领域工作了20多年，担任过由Ralph M. Steinman医学博士领导的实验室的主任，或得了2011年诺贝尔生理医学奖。她目前是洛克菲勒大学细胞生理学和免疫学实验室的高级主治医生和临床研究副教授。2002年到2003年，在加入洛克菲勒大学前，她是纽约国际艾滋病疫苗行动组织一个科学家。1996年到2002年，她是 Walter Reed Army Institute of Research的医学、病理学家，作为Armed Force Institute of Pathology 员工住在华盛顿特区。她在华盛顿乔治敦大学爱因斯坦医学院开始她外科手术的职业生涯，并在纽约多家医院包括Buffalo General，、Hospital New York和 the Manhattan Eye, Ear and Throat Hospital工作过。她取得了韦尔斯利学院学位和芝加哥拉什医学院的医学博士学位。
Sarah J. Schlesinger,has served as a member of Armata Pharmaceuticals, Inc. board of directors since February 2020. She also currently serves as a member of the Board of Directors of Innoviva, Inc., serves as its lead independent director, and serves on its Compensation Committee and Audit Committee and is the chairperson of the Nominating/Corporate Governance Committee. Dr. Schlesinger is an Associate Professor of Clinical Investigation at Rockefeller University and Senior Attending Physician at Rockefeller University Hospital. Dr. Schlesinger was The Clinical Director of the laboratory of Dr. Ralph Steinman (Nobel Laureate 2011) from 2002 until his death in 2011. Dr. Schlesinger led the Dendritic Cell section of the Division of Retrovirology at the Walter Reed Army Institute of Research and was also a member of the Division of Infectious and Parasitic Disease Pathology at the Armed Forces Institute of Pathology from 1994 to 2002. In 2002, Dr. Schlesinger rejoined Rockefeller University and began working with the International AIDS Vaccine Initiative as a Scientist in Vaccine Research and Design. Dr. Schlesinger has been a member of Rockefeller University Hospital's Institutional Review Board ("IRB") (Ethics Committee) since 2003 and previously served as IRB's vice-chairperson. In 2017 she assumed the position of chairperson of the IRB. She is currently the director of the education and training programs at Rockefeller University Center for Clinical and Translational Science. Dr. Schlesinger currently serves on the board of two non-profit organizations: the AIDS Vaccines Advocacy Coalition, and The Hastings Center, the pre-eminent center for the study of bioethics. Dr. Schlesinger served as an independent corporate director of Ariad Pharmaceuticals from 2013 until its sale to Takeda Pharmaceutical Company Limited in 2017. She also served as an independent corporate director of The Medicines Company from 2018 until its acquisition by Novartis in 2020. Dr. Schlesinger has a B.A. from Wellesley College and a M.D. from Rush Medical College in Chicago, Illinois. She trained in Anatomic Pathology at The New York Hospital where she served as Chief Resident. Dr. Schlesinger has demonstrated leadership in her field and her substantial knowledge of Armata Pharmaceuticals, Inc. industry contributed to Armata Pharmaceuticals, Inc. conclusion that she should serve as a director. - Sarah J. Schlesinger医学博士在细胞免疫领域工作了20多年，担任过由Ralph M. Steinman医学博士领导的实验室的主任，或得了2011年诺贝尔生理医学奖。她目前是洛克菲勒大学细胞生理学和免疫学实验室的高级主治医生和临床研究副教授。2002年到2003年，在加入洛克菲勒大学前，她是纽约国际艾滋病疫苗行动组织一个科学家。1996年到2002年，她是 Walter Reed Army Institute of Research的医学、病理学家，作为Armed Force Institute of Pathology 员工住在华盛顿特区。她在华盛顿乔治敦大学爱因斯坦医学院开始她外科手术的职业生涯，并在纽约多家医院包括Buffalo General，、Hospital New York和 the Manhattan Eye, Ear and Throat Hospital工作过。她取得了韦尔斯利学院学位和芝加哥拉什医学院的医学博士学位。
- Sarah J. Schlesinger,has served as a member of Armata Pharmaceuticals, Inc. board of directors since February 2020. She also currently serves as a member of the Board of Directors of Innoviva, Inc., serves as its lead independent director, and serves on its Compensation Committee and Audit Committee and is the chairperson of the Nominating/Corporate Governance Committee. Dr. Schlesinger is an Associate Professor of Clinical Investigation at Rockefeller University and Senior Attending Physician at Rockefeller University Hospital. Dr. Schlesinger was The Clinical Director of the laboratory of Dr. Ralph Steinman (Nobel Laureate 2011) from 2002 until his death in 2011. Dr. Schlesinger led the Dendritic Cell section of the Division of Retrovirology at the Walter Reed Army Institute of Research and was also a member of the Division of Infectious and Parasitic Disease Pathology at the Armed Forces Institute of Pathology from 1994 to 2002. In 2002, Dr. Schlesinger rejoined Rockefeller University and began working with the International AIDS Vaccine Initiative as a Scientist in Vaccine Research and Design. Dr. Schlesinger has been a member of Rockefeller University Hospital's Institutional Review Board ("IRB") (Ethics Committee) since 2003 and previously served as IRB's vice-chairperson. In 2017 she assumed the position of chairperson of the IRB. She is currently the director of the education and training programs at Rockefeller University Center for Clinical and Translational Science. Dr. Schlesinger currently serves on the board of two non-profit organizations: the AIDS Vaccines Advocacy Coalition, and The Hastings Center, the pre-eminent center for the study of bioethics. Dr. Schlesinger served as an independent corporate director of Ariad Pharmaceuticals from 2013 until its sale to Takeda Pharmaceutical Company Limited in 2017. She also served as an independent corporate director of The Medicines Company from 2018 until its acquisition by Novartis in 2020. Dr. Schlesinger has a B.A. from Wellesley College and a M.D. from Rush Medical College in Chicago, Illinois. She trained in Anatomic Pathology at The New York Hospital where she served as Chief Resident. Dr. Schlesinger has demonstrated leadership in her field and her substantial knowledge of Armata Pharmaceuticals, Inc. industry contributed to Armata Pharmaceuticals, Inc. conclusion that she should serve as a director.
高管简历
中英对照 | 中文 | 英文- Stephen M. Rodin
Stephen M. Rodin自2014年3月起担任公司高级副总裁、高级副总裁和秘书。他还从2010年3月到2014年3月担任副总法律顾问；2007年10月到2010年3月担任首席顾问。2007年10月之前，他担任律师事务所Proskauer Rose LLP纽约办事处的合伙人，他的执业范围主要是公司、商业银行和证券法律。 Rodin持有Georgetown University文学学士学位以及Vanderbilt University Law School法律博士学位。
Stephen M. Rodin has been our general counsel and secretary since March 2014. He also served as our deputy general counsel from March 2010 to March 2014 and associate general counsel from October 2007 to March 2010. Prior to October 2007 Mr. Rodin was an attorney at the law firm of Proskauer Rose LLP in New York where his practice focused on corporate, commercial and securities law. Mr. Rodin received an A.B. from Georgetown University and a J.D. from Vanderbilt University Law School.- Stephen M. Rodin自2014年3月起担任公司高级副总裁、高级副总裁和秘书。他还从2010年3月到2014年3月担任副总法律顾问；2007年10月到2010年3月担任首席顾问。2007年10月之前，他担任律师事务所Proskauer Rose LLP纽约办事处的合伙人，他的执业范围主要是公司、商业银行和证券法律。 Rodin持有Georgetown University文学学士学位以及Vanderbilt University Law School法律博士学位。
- Stephen M. Rodin has been our general counsel and secretary since March 2014. He also served as our deputy general counsel from March 2010 to March 2014 and associate general counsel from October 2007 to March 2010. Prior to October 2007 Mr. Rodin was an attorney at the law firm of Proskauer Rose LLP in New York where his practice focused on corporate, commercial and securities law. Mr. Rodin received an A.B. from Georgetown University and a J.D. from Vanderbilt University Law School.
- Chris Cox
Chris Cox，于2016年2月加入公司，担任执行副总裁兼首席公司开发官。加入我们之前，他曾担任公司律师20年以上，最近任职Cadwalader, Wickersham & Taft LLP，在那里他曾担任公司的公司集团的联席主席，以及其管理委员会的成员。他于2012年1月加入Cadwalader公司。此前，他曾担任Cahill Gordon & Reindel LLP的合伙人。他一直担任Datawatch Corporation的董事（2012年8月以来）。他获得the University of Missouri的学士学位、法学博士学位。
Chris Cox has been an executive vice president and our chief corporate development officer since February 2016. Mr. Cox has been a corporate attorney for over 20 years, most recently at Cadwalader, which he joined in January 2012. He was co-chair of Cadwalader’s corporate group and a member of its management committee until February 2016 was senior counsel of the firm from February 2016 until January 2018 and has been a partner of the firm since January 2018. Prior to January 2012 he was a partner at Cahill Gordon & Reindel. Mr. Cox has been a director of Datawatch Corporation since August 2012. He received a B.S. and a J.D. from the University of Missouri.- Chris Cox，于2016年2月加入公司，担任执行副总裁兼首席公司开发官。加入我们之前，他曾担任公司律师20年以上，最近任职Cadwalader, Wickersham & Taft LLP，在那里他曾担任公司的公司集团的联席主席，以及其管理委员会的成员。他于2012年1月加入Cadwalader公司。此前，他曾担任Cahill Gordon & Reindel LLP的合伙人。他一直担任Datawatch Corporation的董事（2012年8月以来）。他获得the University of Missouri的学士学位、法学博士学位。
- Chris Cox has been an executive vice president and our chief corporate development officer since February 2016. Mr. Cox has been a corporate attorney for over 20 years, most recently at Cadwalader, which he joined in January 2012. He was co-chair of Cadwalader’s corporate group and a member of its management committee until February 2016 was senior counsel of the firm from February 2016 until January 2018 and has been a partner of the firm since January 2018. Prior to January 2012 he was a partner at Cahill Gordon & Reindel. Mr. Cox has been a director of Datawatch Corporation since August 2012. He received a B.S. and a J.D. from the University of Missouri.
- Christopher J. Visioli
ChristopherJ.Visioli自2018年3月以来一直担任我们的首席财务官兼财务主管。他此前曾担任我们的高级副总裁，财务战略（2015年1月至2018年3月），以及我们的Vice President心血管护理（2013年1月至2014年12月）。Visioli先生于2003年6月加入我们，并在该组织担任过各种领导职务，包括心血管护理单位的财务，业务发展，投资者关系，战略，计划和业务领导。他曾领导该组织的许多努力，除了领导长期战略和财务规划工作外，还获得产品和建立伙伴关系。在加入我们之前和进入商学院之前，Visioli先生是Ernst&Young LLP的管理顾问。Visioli先生在康奈尔大学（Cornell University）获得电气工程学士学位，并在哥伦比亚商学院（Columbia Business School）获得工商管理硕士学位。
Christopher J. Visioli,has served as Metsera, Inc. Chief Financial Officer since October 2024 and Chief Business Officer since August 2023. Since September 2020, Mr. Visioli has also served as Partner of Population Health Partners, L.P., a life sciences investment firm. Prior to that, Mr. Visioli held a number of leadership roles at The Medicines Company from June 2003 to May 2020, most recently as its Chief Financial Officer. Prior to that, Mr. Visioli was a management consultant at Ernst & Young. Mr. Visioli holds an M.B.A. from Columbia Business School and a B.S. in Electrical Engineering from Cornell University.- ChristopherJ.Visioli自2018年3月以来一直担任我们的首席财务官兼财务主管。他此前曾担任我们的高级副总裁，财务战略（2015年1月至2018年3月），以及我们的Vice President心血管护理（2013年1月至2014年12月）。Visioli先生于2003年6月加入我们，并在该组织担任过各种领导职务，包括心血管护理单位的财务，业务发展，投资者关系，战略，计划和业务领导。他曾领导该组织的许多努力，除了领导长期战略和财务规划工作外，还获得产品和建立伙伴关系。在加入我们之前和进入商学院之前，Visioli先生是Ernst&Young LLP的管理顾问。Visioli先生在康奈尔大学（Cornell University）获得电气工程学士学位，并在哥伦比亚商学院（Columbia Business School）获得工商管理硕士学位。
- Christopher J. Visioli,has served as Metsera, Inc. Chief Financial Officer since October 2024 and Chief Business Officer since August 2023. Since September 2020, Mr. Visioli has also served as Partner of Population Health Partners, L.P., a life sciences investment firm. Prior to that, Mr. Visioli held a number of leadership roles at The Medicines Company from June 2003 to May 2020, most recently as its Chief Financial Officer. Prior to that, Mr. Visioli was a management consultant at Ernst & Young. Mr. Visioli holds an M.B.A. from Columbia Business School and a B.S. in Electrical Engineering from Cornell University.
- Clive A. Meanwell
Clive A. Meanwell是一位创始人，自1996年以来一直担任董事。他自2012年2月起担任Metsera，Inc.首席执行官，2009年10月至2012年2月担任Metsera，Inc.首席执行官兼总裁，2004年8月至2009年10月担任Metsera，Inc.总裁，2004年8月至2004年12月担任Metsera，Inc.执行董事长，2001年9月至2004年8月担任Metsera，Inc.执行董事长，1996年至2001年9月担任Metsera，Inc.首席执行官兼总裁。Meanwell博士还曾于2001年9月至2015年8月担任Metsera，Inc.董事会主席。Meanwell博士是瑞士投资公司BB Biotech的副董事长。从1995年到1996年，Meanwell博士是风险投资公司MPM Capital，L.P.的合伙人兼董事总经理。1986-1995年，Meanwell博士在制药公司Hoffmann-La Roche，Inc.担任过多个职位，包括1992-1995年的高级副总裁、1991-1992年的副总裁和1986-1991年的产品开发总监。Meanwell博士在英国伯明翰大学获得医学博士、工商管理硕士和博士学位（M.D。）。
Clive A. Meanwell,has served as Metsera, Inc. Executive Chairman of the Board of Directors since September 2024 and as Metsera, Inc. Founder and a member of Metsera, Inc. board of directors since Metsera, Inc. inception in June 2022. Dr. Meanwell previously served as Metsera, Inc. Chief Executive Officer from March 2023 to September 2024. Dr. Meanwell has served as a director of Fractyl Health, Inc., a publicly-held metabolic therapeutics company since June 2021. Dr. Meanwell is a Co-Founder of Population Health Partners, L.P., a life sciences investment firm, and, since May 2020 has served as its Chairman and Managing Partner, as well as a managing member of Population Health Partners GP, LLC, its General Partner. Since January 2003, Dr. Meanwell has served as Vice Chairman of BB Biotech AG, a publicly-held Swiss biotechnology investment company, where he has also served as a director since 2004. Dr. Meanwell founded and served as Executive Chairman, Chief Executive Officer, and Director of The Medicines Company, a biopharmaceutical company focused on cardiovascular and infectious diseases and surgery, from 1997 to December 2018, and as a Director and Chief Innovation Officer from December 2018 to January 2020, prior to its sale to Novartis in January 2020. Prior to his founding of The Medicines Company, Dr. Meanwell was a Partner at MPM Capital, a venture capital firm. Before then, he held leadership roles of increasing scope at Roche worldwide, culminating as Senior Vice President and Director in the pharmaceutical division. Dr. Meanwell began his career in cancer treatment and research. He holds an M.B., Ch.B. and M.D. magna cum laude from the University of Birmingham, United Kingdom.- Clive A. Meanwell是一位创始人，自1996年以来一直担任董事。他自2012年2月起担任Metsera，Inc.首席执行官，2009年10月至2012年2月担任Metsera，Inc.首席执行官兼总裁，2004年8月至2009年10月担任Metsera，Inc.总裁，2004年8月至2004年12月担任Metsera，Inc.执行董事长，2001年9月至2004年8月担任Metsera，Inc.执行董事长，1996年至2001年9月担任Metsera，Inc.首席执行官兼总裁。Meanwell博士还曾于2001年9月至2015年8月担任Metsera，Inc.董事会主席。Meanwell博士是瑞士投资公司BB Biotech的副董事长。从1995年到1996年，Meanwell博士是风险投资公司MPM Capital，L.P.的合伙人兼董事总经理。1986-1995年，Meanwell博士在制药公司Hoffmann-La Roche，Inc.担任过多个职位，包括1992-1995年的高级副总裁、1991-1992年的副总裁和1986-1991年的产品开发总监。Meanwell博士在英国伯明翰大学获得医学博士、工商管理硕士和博士学位（M.D。）。
- Clive A. Meanwell,has served as Metsera, Inc. Executive Chairman of the Board of Directors since September 2024 and as Metsera, Inc. Founder and a member of Metsera, Inc. board of directors since Metsera, Inc. inception in June 2022. Dr. Meanwell previously served as Metsera, Inc. Chief Executive Officer from March 2023 to September 2024. Dr. Meanwell has served as a director of Fractyl Health, Inc., a publicly-held metabolic therapeutics company since June 2021. Dr. Meanwell is a Co-Founder of Population Health Partners, L.P., a life sciences investment firm, and, since May 2020 has served as its Chairman and Managing Partner, as well as a managing member of Population Health Partners GP, LLC, its General Partner. Since January 2003, Dr. Meanwell has served as Vice Chairman of BB Biotech AG, a publicly-held Swiss biotechnology investment company, where he has also served as a director since 2004. Dr. Meanwell founded and served as Executive Chairman, Chief Executive Officer, and Director of The Medicines Company, a biopharmaceutical company focused on cardiovascular and infectious diseases and surgery, from 1997 to December 2018, and as a Director and Chief Innovation Officer from December 2018 to January 2020, prior to its sale to Novartis in January 2020. Prior to his founding of The Medicines Company, Dr. Meanwell was a Partner at MPM Capital, a venture capital firm. Before then, he held leadership roles of increasing scope at Roche worldwide, culminating as Senior Vice President and Director in the pharmaceutical division. Dr. Meanwell began his career in cancer treatment and research. He holds an M.B., Ch.B. and M.D. magna cum laude from the University of Birmingham, United Kingdom.
- Fredric N. Eshelman
Fredric N. Eshelman，2009年7月起，担任本公司的执行董事长。1990年7月至2009年7月，他担任本公司的首席执行官；1993年7月至2009年7月，担任副董事长。他是本公司前身的创始人，并担任首席执行官，直到1989年将其出售给本公司。回到本公司之前，1989-1990，他是Glaxo Holdings plc子公司Glaxo Inc.的开发高级副总裁、董事。他现为Furiex Pharmaceuticals, Inc.的董事长、顾问。
Fredric N. Eshelman,Dr. Eshelman was the founder of Pharmaceutical Product Development, Inc. PPD and founding chairman of Furiex Pharmaceuticals, Inc. In 2014 Dr. Eshelman founded Eshelman Ventures, LLC, an investment company focused on healthcare companies. From 2009 to 2014 Dr. Eshelman served as chairman of the Board of Furiex. From 2009 to 2011 he served as executive chairman of PPD. He also served as chief executive officer of PPD from 1990 to 2009 and as vice chairman of its Board of Directors from 1993 to 2009. Dr. Eshelman currently serves on the board of directors of Valeant Pharmaceuticals International, Inc. and G1 Therapeutics, Inc. Dr. Eshelman received a bachelor’s degree in pharmacy from UNC Chapel Hill and a doctorate in pharmacy from the University of Cincinnati, and he completed an OPM program at Harvard University.- Fredric N. Eshelman，2009年7月起，担任本公司的执行董事长。1990年7月至2009年7月，他担任本公司的首席执行官；1993年7月至2009年7月，担任副董事长。他是本公司前身的创始人，并担任首席执行官，直到1989年将其出售给本公司。回到本公司之前，1989-1990，他是Glaxo Holdings plc子公司Glaxo Inc.的开发高级副总裁、董事。他现为Furiex Pharmaceuticals, Inc.的董事长、顾问。
- Fredric N. Eshelman,Dr. Eshelman was the founder of Pharmaceutical Product Development, Inc. PPD and founding chairman of Furiex Pharmaceuticals, Inc. In 2014 Dr. Eshelman founded Eshelman Ventures, LLC, an investment company focused on healthcare companies. From 2009 to 2014 Dr. Eshelman served as chairman of the Board of Furiex. From 2009 to 2011 he served as executive chairman of PPD. He also served as chief executive officer of PPD from 1990 to 2009 and as vice chairman of its Board of Directors from 1993 to 2009. Dr. Eshelman currently serves on the board of directors of Valeant Pharmaceuticals International, Inc. and G1 Therapeutics, Inc. Dr. Eshelman received a bachelor’s degree in pharmacy from UNC Chapel Hill and a doctorate in pharmacy from the University of Cincinnati, and he completed an OPM program at Harvard University.
- Fredric N. Eshelman
Fredric N. Eshelman，他是一名药学博士。自本公司于2009年成立以来，他在本公司担任董事会主席。自2009年7月至2011年12月，他在Pharmaceutical Product Development公司 （"PPD"）担任董事会执行主席。该公司于2011年12月进行资本清算。自1990年7月至2009年7月，他在PPD公司担任首席执行官。自1993年7月至2009年7月，他担任董事会副总裁。他建立了PPD公司的前身公司并担任了首席执行官，直至1989年该公司被PPD公司收购。自1989年至1990年，他在Glaxo公司担任开发方面的高级副总裁以及董事。Glaxo公司是Glaxo Holdings plc公司的子公司。他在美国北卡罗来纳州生物技术中心担任董事。
Fredric N. Eshelman,was appointed the Executive Chairman of Aravive, Inc. on January 3, 2022 and has served as the non-executive Chairman of the Board of Directors from April 8, 2020 until his appointment as Executive Chairman of Aravive, Inc. Dr. Eshelman is the Founder of Eshelman Ventures, LLC, an investment company primarily interested in healthcare companies. Previously, he founded and served as Chairman and Chief Executive Officer of Pharmaceutical Product Development, Inc. (PPDI) prior to the sale of the company to private equity interests. After PPD, he served as founding chairman and was the largest shareholder of Furiex Pharmaceuticals, Inc. (FURX), a company which in-licensed and rapidly developed new medicines. Furiex was sold to Forest Laboratories Inc. (which was later acquired by Actavis) in 2014. His career has also included positions as SVP development and board member of the former Glaxo, Inc., as well as management positions with Beecham Laboratories and Boehringer Mannheim Pharmaceuticals. Dr. Eshelman is also a member of the Board of Directors of, Amplitude Healthcare Acquisition Corp. and Eyenovia Inc. He is currently chairman of several biotech companies and previously was chairman of The Medicines Company (MDCO) and was on the board of Bausch Health (BHC) G1 Therapeutics, Inc. Dr. Eshelman has served on the executive committee of the Medical Foundation of North Carolina and was appointed by the North Carolina General Assembly to serve on the Board of Governors for the state's multi-campus university system (chair of audit committee), as well as the North Carolina Biotechnology Center. In addition, he chairs the board of visitors for the School of Pharmacy at University of North Carolina at Charlotte (UNC-CH). The school was named the UNC Eshelman School of Pharmacy in recognition of his many contributions to the school and the profession.He has received many awards including the Davie and Distinguished Service Awards from UNC, outstanding alumnus from both the UNC and University of Cincinnati schools of pharmacy, Life Science Leadership Award (CED) and the North Carolina Biotech Hall of Fame. Dr. Eshelman received the doctor of pharmacy from the University of Cincinnati, completed a residency at Cincinnati General Hospital, and received a BS Pharm from UNC-CH. He completed the OPM program at Harvard Business School. Dr. Eshelman also received an honorary doctor of science from UNC-CH.- Fredric N. Eshelman，他是一名药学博士。自本公司于2009年成立以来，他在本公司担任董事会主席。自2009年7月至2011年12月，他在Pharmaceutical Product Development公司 （"PPD"）担任董事会执行主席。该公司于2011年12月进行资本清算。自1990年7月至2009年7月，他在PPD公司担任首席执行官。自1993年7月至2009年7月，他担任董事会副总裁。他建立了PPD公司的前身公司并担任了首席执行官，直至1989年该公司被PPD公司收购。自1989年至1990年，他在Glaxo公司担任开发方面的高级副总裁以及董事。Glaxo公司是Glaxo Holdings plc公司的子公司。他在美国北卡罗来纳州生物技术中心担任董事。
- Fredric N. Eshelman,was appointed the Executive Chairman of Aravive, Inc. on January 3, 2022 and has served as the non-executive Chairman of the Board of Directors from April 8, 2020 until his appointment as Executive Chairman of Aravive, Inc. Dr. Eshelman is the Founder of Eshelman Ventures, LLC, an investment company primarily interested in healthcare companies. Previously, he founded and served as Chairman and Chief Executive Officer of Pharmaceutical Product Development, Inc. (PPDI) prior to the sale of the company to private equity interests. After PPD, he served as founding chairman and was the largest shareholder of Furiex Pharmaceuticals, Inc. (FURX), a company which in-licensed and rapidly developed new medicines. Furiex was sold to Forest Laboratories Inc. (which was later acquired by Actavis) in 2014. His career has also included positions as SVP development and board member of the former Glaxo, Inc., as well as management positions with Beecham Laboratories and Boehringer Mannheim Pharmaceuticals. Dr. Eshelman is also a member of the Board of Directors of, Amplitude Healthcare Acquisition Corp. and Eyenovia Inc. He is currently chairman of several biotech companies and previously was chairman of The Medicines Company (MDCO) and was on the board of Bausch Health (BHC) G1 Therapeutics, Inc. Dr. Eshelman has served on the executive committee of the Medical Foundation of North Carolina and was appointed by the North Carolina General Assembly to serve on the Board of Governors for the state's multi-campus university system (chair of audit committee), as well as the North Carolina Biotechnology Center. In addition, he chairs the board of visitors for the School of Pharmacy at University of North Carolina at Charlotte (UNC-CH). The school was named the UNC Eshelman School of Pharmacy in recognition of his many contributions to the school and the profession.He has received many awards including the Davie and Distinguished Service Awards from UNC, outstanding alumnus from both the UNC and University of Cincinnati schools of pharmacy, Life Science Leadership Award (CED) and the North Carolina Biotech Hall of Fame. Dr. Eshelman received the doctor of pharmacy from the University of Cincinnati, completed a residency at Cincinnati General Hospital, and received a BS Pharm from UNC-CH. He completed the OPM program at Harvard Business School. Dr. Eshelman also received an honorary doctor of science from UNC-CH.